NasdaqGS - Nasdaq Real Time Price USD

Karyopharm Therapeutics Inc. (KPTI)

1.1700

-0.1100

(-8.59%)

At close: 4:00 PM EDT

1.1700

0.00

(0.00%)

After hours: 4:20 PM EDT

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 79,800 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of March 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Na

PR Newswire 18 days ago

KPTI
-8.59%
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m. ET in Miami Beach, FL.

PR Newswire last month

KPTI
-8.59%
Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...

President and CEO Richard Paulson executed a sale of 99,844 shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) on March 1, 2024, according to a recent SEC Filing.

GuruFocus.com last month

KPTI
-8.59%
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript February 29, 2024 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.36 EPS, expectations were $-0.29. FDS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name […]

Insider Monkey last month

KPTI
-8.59%
Q4 2023 Karyopharm Therapeutics Inc Earnings Call

Q4 2023 Karyopharm Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

KPTI
-8.59%
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

KPTI earnings call for the period ending December 31, 2023.

Motley Fool last month

KPTI
-8.59%
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

KPTI
-8.59%
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023. In addition, Karyopharm highlighted select corporate milestones and provided an overview of its key clinical development programs.

PR Newswire last month

KPTI
-8.59%
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum. This is a good time to remind you of all the reasons you shouldn’t buy biotech penny stocks. The first reason centers on the last two words. While many of these companies may claim advanced clinical data and whatnot, the reality is that many if not most players in this field wil

InvestorPlace last month

ATNM

KPTI
-8.59%
OTLK
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 29, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 29, 2024, to discuss the financial results and other company updates.

PR Newswire last month

KPTI
-8.59%
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks last month

XNCR

KPTI
-8.59%
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

ARDX

KPTI
-8.59%
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

KPTI
-8.59%
PTCT
+2.55%
Karyopharm Therapeutics (NASDAQ:KPTI) adds US$104m to market cap in the past 7 days, though investors from three years ago are still down 90%

It is a pleasure to report that the Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is up 139% in the last quarter. But...

Simply Wall St. 2 months ago

KPTI
-8.59%
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2023 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2023 achievements and 2024 objectives.

PR Newswire 3 months ago

KPTI
-8.59%
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 42nd Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 10 at 2:15 p.m. PT, followed by a question-and-answer breakout session at 2:35 p.m. PT.

PR Newswire 3 months ago

KPTI
-8.59%
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced long-term follow up of treatment-naïve patients with myelofibrosis (MF) who participated in the Phase 1 portion of its study evaluating once-weekly selinexor in combination with ruxolitinib (NCT04562389). The data, featured in an oral presentation at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023), show patients treated with 60

PR Newswire 4 months ago

KPTI
-8.59%
Great week for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) institutional investors after losing 84% over the previous year

Key Insights Given the large stake in the stock by institutions, Karyopharm Therapeutics' stock price might be...

Simply Wall St. 4 months ago

KPTI
-8.59%
Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November:

PR Newswire 5 months ago

KPTI
-8.59%
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated long-term safety and efficacy data from a pre-specified exploratory subgroup analysis of the SIENDO study (NCT03555422) in patients with advanced or recurrent TP53 wild-type endometrial cancer at the International Gynecological Cancer Society (IGCS) Annual Global Meeting in Seoul, South Korea.

PR Newswire 5 months ago

KPTI
-8.59%

Performance Overview

Return	KPTI	S&P 500
YTD	+35.26%	+4.14%
1-Year	-71.81%	+19.55%
3-Year	-87.95%	+18.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript

Q4 2023 Karyopharm Therapeutics Inc Earnings Call

Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know

Karyopharm Therapeutics (NASDAQ:KPTI) adds US$104m to market cap in the past 7 days, though investors from three years ago are still down 90%

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Great week for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) institutional investors after losing 84% over the previous year

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study

Performance Overview